{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T19:57:37Z","timestamp":1793476657298,"version":"4.5.0"},"reference-count":64,"publisher":"Bentham Science Publishers Ltd.","issue":"18","funder":[{"DOI":"10.13039\/501100017577","name":"Zhejiang public welfare fund project, China","doi-asserted-by":"publisher","award":["GF20H300011"],"award-info":[{"award-number":["GF20H300011"]}],"id":[{"id":"10.13039\/501100017577","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Cantharidin (CTD) is a highly toxic substance which can be\nused to treat a variety of cancers. However, the clinical application of CTD is restricted\ndue to the serious side effects. In recent years, screening its analogues, exploring the\nmechanism of action and using combinatory therapy with certain substances are considered\nto be feasible methods which can reduce side effects and improve the therapeutic activity\nof CTD. This review aims to describe SAR (structure-activity relationship) of CTD\nanalogues, CTD induction mechanisms, and combinatory therapy exploration.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>We searched for research about CTD by entering the database. Important information\nwas screened and extracted purposefully, including SAR, mechanisms, methods,\netc. Finally, these contents were unified into a framework to form a review.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Some CTD analogues with imidazolium salt or double bonds at C-5 and C-6 positions\ndemonstrate good anticancer activity. Through introducing methyl and acetoxy\ngroups at the C-1 or C-4 position, the inhibitory effect of PP was weakened or even inactivated.\nRemoving the two methyl groups of C-2 and C-3 can reduce side effects and improve\nefficacy. Replacing methyl with fluorine can also improve the activity and reduce\ntoxicity. Water solubility and bioavailability could be improved by opening the five fivemembered\nanhydride ring to form carboxylic acid, salt, amide, and ester derivatives. The\nanticancer mechanism can be divided into the following aspects, including inhibiting cell\ninvasion and metastasis, inducing apoptosis, regulating cell cycle and enhancing immunity.\nThe proper formulation of CTD and its analogues (liposomes, nanoparticles and micelles)\ncan improve the targeting of liver cancer and reduce toxic and side effects. CTD\ncombined with anti-angiogenic therapeutics (Ginsenoside Rg3, Bevacizumab, Apatinib\nand Endostar) showed additive anti-pancreatic cancer effects.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>It was found that the potential mechanism was closely related to multi-channel\nand multi-target interactions, which provided a guiding direction for the later exploration\nof new clinical therapeutic applications. However, some detailed mechanisms are\nstill unclear, and more evidence is required to verify. In addition, the new methods to improve\nthe therapeutic potential of CTD and its analogues still need more clinical trials to\nbe tested in the future. This prospect is very broad and worthy of further study.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867330666221103151537","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T07:22:43Z","timestamp":1667546563000},"page":"2006-2019","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Exploring Cantharidin and its Analogues as Anticancer Agents: A\nReview"],"prefix":"10.2174","volume":"30","author":[{"given":"Shaoting","family":"Li","sequence":"first","affiliation":[{"name":"Chemistry and Chemical Engineering Institute, Shaoxing University, Shaoxing 312000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xufeng","family":"Wu","sequence":"additional","affiliation":[{"name":"Research\n&amp; Development Center, Zhejiang Medicine Co. Ltd, Shaoxing, 312500, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Fan","sequence":"additional","affiliation":[{"name":"Research\n&amp; Development Center, Zhejiang Medicine Co. Ltd, Shaoxing, 312500, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui","family":"Du","sequence":"additional","affiliation":[{"name":"Chemistry and Chemical Engineering Institute, Shaoxing University, Shaoxing 312000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Deng","sequence":"additional","affiliation":[{"name":"Chemistry and Chemical Engineering Institute, Shaoxing University, Shaoxing 312000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"111285","DOI":"10.1016\/j.colsurfb.2020.111285","volume":"196","author":"Yao H.","year":"2020","unstructured":"Yao H.; Zhao J.; Wang Z.; Lv J.; Du G.; Jin Y.; Zhang Y.; Song S.; Han G.; Enhanced anticancer efficacy of cantharidin by mPEG-PLGA micellar encapsulation: An effective strategy for application of a poisonous traditional Chinese medicine. Colloids Surf B Biointerfaces 2020,196,111285","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.bcp.2016.03.011","volume":"109","author":"Chattopadhyay D.","year":"2016","unstructured":"Chattopadhyay D.; Swingle M.R.; Salter E.A.; Wood E.; D\u2019Arcy B.; Zivanov C.; Abney K.; Musiyenko A.; Rusin S.F.; Kettenbach A.; Yet L.; Schroeder C.E.; Golden J.E.; Dunham W.H.; Gingras A.C.; Banerjee S.; Forbes D.; Wierzbicki A.; Honkanen R.E.; Crystal structures and mutagenesis of PPP-family ser\/thr protein phosphatases elucidate the selectivity of cantharidin and novel norcantharidin-based inhibitors of PP5C. Biochem Pharmacol 2016,109,14-26","journal-title":"Biochem Pharmacol"},{"key":"ref=3","first-page":"43229799","volume":"2013","author":"Ghoneim K.","year":"2013","unstructured":"Ghoneim K.; Cantharidin toxicosis to animal and human in the world: A review. Stand Res J Toxicol Environ Health Sci 2013,2013,43229799","journal-title":"Stand Res J Toxicol Environ Health Sci"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3390\/ani11010220","volume":"11","author":"Jakovac-Strajn B.","year":"2021","unstructured":"Jakovac-Strajn B.; Brozi\u0107 D.; Tav\u010dar-Kalcher G.; Babi\u010d J.; Trilar T.; Vengust M.; Entomological surveillance and cantharidin concentrations in Mylabris variabilis and Epicauta rufidorsum blister beetles in slovenia. Animals 2021,11(1),220-228","journal-title":"Animals"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/0145-2126(91)90163-N","volume":"15","author":"Yi S.","year":"1991","unstructured":"Yi S.; Wass J.; Vincent P.; Iland H.; Inhibitory effect of norcantharidin on K562 human myeloid leukemia cells in vitro. Leuk Res 1991,15(10),883-886","journal-title":"Leuk Res"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/jamadermatol.2017.4531","volume":"154","author":"Falck B.","year":"2018","unstructured":"Falck B.; Spanish Fly\u2014Cantharidin\u2019s Alter Ego. JAMA Dermatol 2018,154(1),51-51","journal-title":"JAMA Dermatol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/ens.12364","volume":"22","author":"Gisondi S.","year":"2019","unstructured":"Gisondi S.; Gasperi T.; Roma E.; Tomai P.; Gentili A.; Vignoli L.; Bologna M.A.; Mancini E.; Cantharidin content in two Mediterranean species of blister beetles, Lydus trimaculatus and Mylabris variabilis (Coleoptera: Meloidae). Entomol Sci 2019,22(3),258-263","journal-title":"Entomol Sci"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jep.2011.12.041","volume":"140","author":"Wang S.","year":"2012","unstructured":"Wang S.; Wu X.; Tan M.; Gong J.; Tan W.; Bian B.; Chen M.; Wang Y.; Fighting fire with fire: Poisonous Chinese herbal medicine for cancer therapy. J Ethnopharmacol 2012,140(1),33-45","journal-title":"J Ethnopharmacol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1001\/jamadermatol.2020.3238","volume":"156","author":"Eichenfield L.F.","year":"2020","unstructured":"Eichenfield L.F.; McFalda W.; Brabec B.; Siegfried E.; Kwong P.; McBride M.; Rieger J.; Willson C.; Davidson M.; Burnett P.; Safety and efficacy of VP-102, a proprietary, drug-device combination product containing cantharidin, 0.7% (w\/v), in children and adults with molluscum contagiosum. JAMA Dermatol 2020,156(12),1315-1323","journal-title":"JAMA Dermatol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13020-020-00338-6","volume":"15","author":"Pan M.S.","year":"2020","unstructured":"Pan M.S.; Cao J.; Fan Y.Z.; Insight into norcantharidin, a small-molecule synthetic compound with potential multi- target anticancer activities. Chin Med 2020,15(1),55-82","journal-title":"Chin Med"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.carbpol.2017.06.072","volume":"174","author":"Jiang Z.","year":"2017","unstructured":"Jiang Z.; Chi J.; Han B.; Liu W.; Preparation and pharmacological evaluation of norcantharidin-conjugated carboxymethyl chitosan in mice bearing hepatocellular carcinoma. Carbohydr Polym 2017,174,282-290","journal-title":"Carbohydr Polym"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"392","DOI":"10.2174\/1871520610909040392","volume":"9","author":"Liu D. W.","year":"2009","unstructured":"Liu D. W.; Chen Z. W.; The effects of cantharidin and cantharidin derivates on tumour cells. Anti-Cancer Agent Med 2009,9(4),392-396","journal-title":"Anti-Cancer Agent Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2174\/092986713804806711","volume":"20","author":"Deng L.P.","year":"2013","unstructured":"Deng L.P.; Dong J.; Cai H.; Wang W.; Cantharidin as an antitumor agent: A retrospective review. Curr Med Chem 2013,20(2),159-166","journal-title":"Curr Med Chem"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"116012","DOI":"10.1016\/j.bmc.2021.116012","volume":"32","author":"Ren Y.","year":"2021","unstructured":"Ren Y.; Kinghorn A.D.; Antitumor potential of the protein phosphatase inhibitor, cantharidin, and selected derivatives. Bioorg Med Chem 2021,32,116012","journal-title":"Bioorg Med Chem"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.7150\/jca.25454","volume":"9","author":"Ma Q.","year":"2018","unstructured":"Ma Q.; Feng Y.; Deng K.; Shao H.; Sui T.; Zhang X.; Sun X.; Jin L.; Ma Z.; Luo G.; Unique responses of hepatocellular carcinoma and cholangiocarcinoma cell lines toward cantharidin and norcantharidin. J Cancer 2018,9(12),2183-2190","journal-title":"J Cancer"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1142\/S0192415X15500366","volume":"43","author":"Su C.C.","year":"2015","unstructured":"Su C.C.; Liu S.H.; Lee K.I.; Huang K.T.; Lu T.H.; Fang K.M.; Wu C.C.; Yen C.C.; Lai C.H.; Su Y.C.; Huang C.F.; Cantharidin induces apoptosis through the calcium\/PKC-regulated endoplasmic reticulum stress pathway in human bladder cancer cells. Am J Chin Med 2015,43(3),581-600","journal-title":"Am J Chin Med"},{"key":"ref=17","first-page":"1243","volume":"37","author":"Kuo J-H.","year":"2010","unstructured":"Kuo J-H.; Chu Y-L.; Yang J-S.; Lin J-P.; Lai K-C.; Kuo H-M.; Hsia T-C.; Chung J-G.; Cantharidin induces apoptosis in human bladder cancer TSGH 8301 cells through mitochondria-dependent signal pathways. Int J Oncol 2010,37(5),1243-1250","journal-title":"Int J Oncol"},{"key":"ref=18","first-page":"243","volume":"2","author":"Zhang Q.","year":"2017","unstructured":"Zhang Q.; Zhu G.; The pathological pattern of seven malignant cancers following Demethylcantharidin. Adv Pharm J 2017,2(6),243-247","journal-title":"Adv Pharm J"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"e31055","DOI":"10.1371\/journal.pone.0031055","volume":"7","author":"Yeh C.B.","year":"2012","unstructured":"Yeh C.B.; Hsieh M.J.; Hsieh Y.H.; Chien M.H.; Chiou H.L.; Yang S.F.; Antimetastatic effects of norcantharidin on hepatocellular carcinoma by transcriptional inhibition of MMP-9 through modulation of NF-kB activity. PLoS One 2012,7(2),e31055","journal-title":"PLoS One"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/0378-8741(89)90062-7","volume":"26","author":"Wang G.S.","year":"1989","unstructured":"Wang G.S.; Medical uses of mylabris in ancient China and recent studies. J Ethnopharmacol 1989,26(2),147-162","journal-title":"J Ethnopharmacol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.2174\/0929867324666170414165253","volume":"25","author":"Wang G.","year":"2018","unstructured":"Wang G.; Dong J.; Deng L.; Overview of cantharidin and its analogues. Curr Med Chem 2018,25(17),2034-2044","journal-title":"Curr Med Chem"},{"key":"ref=22","first-page":"599","volume":"39","author":"Wang G.F.","year":"2017","unstructured":"Wang G.F.; The new developments of cantharidin and its analogues. J Chem Soc Pak 2017,39(4),599-609","journal-title":"J Chem Soc Pak"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.neunet.2021.04.027","volume":"142","author":"Mill\u00e1n A.P.","year":"2021","unstructured":"Mill\u00e1n A.P.; Torres J.J.; Johnson S.; Marro J.; Growth strategy determines the memory and structural properties of brain networks. Neural Netw 2021,142,44-56","journal-title":"Neural Netw"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0960-894X(00)00323-1","volume":"10","author":"McCluskey A.","year":"2000","unstructured":"McCluskey A.; Bowyer M.C.; Collins E.; Sim A.T.R.; Sakoff J.A.; Baldwin M.L.; Anhydride modified cantharidin analogues: Synthesis, inhibition of protein phosphatases 1 and 2A and anticancer activity. Bioorg Med Chem Lett 2000,10(15),1687-1690","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1002\/cmdc.201900180","volume":"14","author":"Hizartzidis L.","year":"2019","unstructured":"Hizartzidis L.; Gilbert J.; Gordon C.P.; Sakoff J.A.; McCluskey A.; Synthesis and cytotoxicity of octahydroepoxyisoindole-7-carboxylic acids and norcantharidin\u2013amide hybrids as norcantharidin analogues. ChemMedChem 2019,14(12),1152-1161","journal-title":"ChemMedChem"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1093\/jee\/toz049","volume":"112","author":"Li Y.","year":"2019","unstructured":"Li Y.; Sun H.; Xi N.; Zhang Y.; Effects of cantharidin and norcantharidin on larval feeding and adult oviposition preferences of the Diamondback Moth (Lepidoptera: Plutellidae). J Econ Entomol 2019,112(4),1634-1637","journal-title":"J Econ Entomol"},{"key":"ref=27","first-page":"107","volume":"23","author":"Wang L.","year":"2021","unstructured":"Wang L.; Zheng S.L.; Lv S.M.; Zhang Y.L.; Wang Y.; Inhibitory mechanism of cantharidin derivatives against Sclerotinia sclerotiorum. Chinese J Pesticide Sci 2021,23(1),107-116","journal-title":"Chinese J Pesticide Sci"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1742-7843.2005.pto960104.x","volume":"96","author":"Massicot F.","year":"2005","unstructured":"Massicot F.; Dutertre-Catella H.; Pham-Huy C.; Liu X.H.; Duc H.T.; Warnet J.M.; In vitro assessment of renal toxicity and inflammatory events of two protein phosphatase inhibitors cantharidin and nor-cantharidin. Basic Clin Pharmacol Toxicol 2005,96(1),26-32","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1002\/jhet.3533","volume":"56","author":"Zhao C.","year":"2019","unstructured":"Zhao C.; Jia J.; Wang X.; Luo C.; Wang Y.; Synthesis of norcantharidin complex salts. J Heterocycl Chem 2019,56(5),1567-1570","journal-title":"J Heterocycl Chem"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1007\/s10753-019-01173-0","volume":"43","author":"Xiao Z.","year":"2020","unstructured":"Xiao Z.; Wen L.; Zeng D.; Yin D.; Zhou X.; Tang C.; Li Y.; Protein phosphatase 2A inhibiting \u03b2-catenin phosphorylation contributes critically to the anti-renal interstitial fibrotic effect of norcantharidin. Inflammation 2020,43(3),878-891","journal-title":"Inflammation"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"5429","DOI":"10.1016\/S0040-4039(01)01056-5","volume":"42","author":"Essers M.","year":"2001","unstructured":"Essers M.; Wibbeling B.; Haufe G.; Synthesis of the first fluorinated cantharidin analogues. Tetrahedron Lett 2001,42(32),5429-5433","journal-title":"Tetrahedron Lett"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/0960-894X(96)00166-7","volume":"6","author":"McCluskey A.","year":"1996","unstructured":"McCluskey A.; Taylor C.; Quinn R.J.; Suganuma M.; Fujiki H.; Inhibition of protein phosphatase 2A by cantharidin analogues. Bioorg Med Chem Lett 1996,6(9),1025-1028","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"9740","DOI":"10.1021\/ja034694y","volume":"125","author":"Baba Y.","year":"2003","unstructured":"Baba Y.; Hirukawa N.; Tanohira N.; Sodeoka M.; Structure-based design of a highly selective catalytic site-directed inhibitor of Ser\/Thr protein phosphatase 2B (calcineurin). J Am Chem Soc 2003,125(32),9740-9749","journal-title":"J Am Chem Soc"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1016\/j.ejmech.2010.01.004","volume":"45","author":"Thaqi A.","year":"2010","unstructured":"Thaqi A.; Scott J.L.; Gilbert J.; Sakoff J.A.; McCluskey A.; Synthesis and biological activity of \u0394-5,6-norcantharimides: Importance of the 5,6-bridge. Eur J Med Chem 2010,45(5),1717-1723","journal-title":"Eur J Med Chem"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejmech.2015.10.049","volume":"107","author":"Manda S.","year":"2016","unstructured":"Manda S.; Sharma S.; Wani A.; Joshi P.; Kumar V.; Guru S.K.; Bharate S.S.; Bhushan S.; Vishwakarma R.A.; Kumar A.; Bharate S.B.; Discovery of a marine-derived bis-indole alkaloid fascaplysin, as a new class of potent P-glycoprotein inducer and establishment of its structure\u2013activity relationship. Eur J Med Chem 2016,107,1-11","journal-title":"Eur J Med Chem"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2174\/1570179414666170824160901","volume":"15","author":"Sun R.R.","year":"2018","unstructured":"Sun R.R.; Guo J.H.; Yang C.; Yang L.J.; Huang C.; Synthesis and antitumor evaluation of novel N-substituted norcantharidin imidazolium derivatives. Curr Org Synth 2018,15(2),237-245","journal-title":"Curr Org Synth"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.2174\/1389557511313080005","volume":"13","author":"Deng L.","year":"2013","unstructured":"Deng L.; Dong J.; Wang W.; Exploiting protein phosphatase inhibitors based on cantharidin analogues for cancer drug discovery. Mini Rev Med Chem 2013,13(8),1166-1176","journal-title":"Mini Rev Med Chem"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1517\/13543776.2011.629190","volume":"21","author":"Deng L.","year":"2011","unstructured":"Deng L.; Tang S.; Norcantharidin analogues: A patent review (2006 \u2013 2010). Expert Opin Ther Pat 2011,21(11),1743-1753","journal-title":"Expert Opin Ther Pat"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0223-5234(00)00186-0","volume":"35","author":"McCluskey A.","year":"2000","unstructured":"McCluskey A.; Keane M.A.; Mudgee L.M.; Sim A.T.R.; Sakoff J.; Quinn R.J.; Anhydride modified cantharidin analogues. Is ring opening important in the inhibition of protein phosphatase 2A? Eur J Med Chem 2000,35(10),957-964","journal-title":"Eur J Med Chem"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"e1800673","DOI":"10.1002\/cbdv.201800673","volume":"16","author":"Pachuta-Stec A.","year":"2019","unstructured":"Pachuta-Stec A.; Nowak R.; Pietrzak W.; Pitucha M.; Synthesis and antioxidant activity of new norcantharidin analogs. Chem Biodivers 2019,16(4),e1800673","journal-title":"Chem Biodivers"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"131754","DOI":"10.1016\/j.tet.2020.131754","volume":"77","author":"Lawrenson S.B.","year":"2021","unstructured":"Lawrenson S.B.; Pearce A.K.; Hart S.; Whitwood A.C.; O\u2019Reilly R.K.; North M.; Synthesis of cytotoxic spirocyclic imides from a biomass-derived oxanorbornene. Tetrahedron 2021,77,131754","journal-title":"Tetrahedron"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"111845","DOI":"10.1016\/j.fct.2020.111845","volume":"146","author":"He T.","year":"2020","unstructured":"He T.; Liu J.; Wang X.; Duan C.; Li X.; Zhang J.; Analysis of cantharidin-induced nephrotoxicity in HK-2 cells using untargeted metabolomics and an integrative network pharmacology analysis. Food Chem Toxicol 2020,146,111845","journal-title":"Food Chem Toxicol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"112986","DOI":"10.1016\/j.fct.2022.112986","volume":"163","author":"He T.","year":"2022","unstructured":"He T.; Wang Q.; Ao J.; Chen K.; Li X.; Zhang J.; Duan C.; Endoplasmic reticulum stress contributes to autophagy and apoptosis in cantharidin-induced nephrotoxicity. Food Chem Toxicol 2022,163,112986","journal-title":"Food Chem Toxicol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1002\/jat.4003","volume":"40","author":"Yu Y.","year":"2020","unstructured":"Yu Y.; Zhang Y.; Zhang J.; Guan C.; Liu L.; Ren L.; Cantharidin-induced acute hepatotoxicity: The role of TNF-\u03b1, IKK-\u03b1, Bcl-2, Bax and caspase3. J Appl Toxicol 2020,40(11),1526-1533","journal-title":"J Appl Toxicol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1002\/jat.3983","volume":"40","author":"Zhang J.","year":"2020","unstructured":"Zhang J.; Chen Q.; Wang L.; Chen K.; Mu W.; Duan C.; Li X.; Study on the mechanism of cantharidin-induced hepatotoxicity in rat using serum and liver metabolomics combined with conventional pathology methods. J Appl Toxicol 2020,40(9),1259-1271","journal-title":"J Appl Toxicol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.toxlet.2020.07.024","volume":"333","author":"Liu F.","year":"2020","unstructured":"Liu F.; Wang X.; Duan C.; Zhang J.; Li X.; Hepatoxicity mechanism of cantharidin-induced liver LO2 cells by LC\u2013MS metabolomics combined traditional approaches. Toxicol Lett 2020,333,49-61","journal-title":"Toxicol Lett"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.3390\/molecules22071052","volume":"22","author":"Zhang X.","year":"2017","unstructured":"Zhang X.; Lin C.C.; Chan W.K.N.; Liu K.L.; Yang Z.J.; Zhang H.Q.; Augmented anticancer effects of cantharidin with liposomal encapsulation: In vitro and in vivo evaluation. Molecules 2017,22(7),1052-1063","journal-title":"Molecules"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.3390\/molecules25143279","volume":"25","author":"Naz F.","year":"2020","unstructured":"Naz F.; Wu Y.; Zhang N.; Yang Z.; Yu C.; Anticancer attributes of cantharidin: Involved molecular mechanisms and pathways. Molecules 2020,25(14),3279-3297","journal-title":"Molecules"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"eabd6299","DOI":"10.1126\/scitranslmed.abd6299","volume":"13","author":"Cohen A.","year":"2021","unstructured":"Cohen A.; Ioannidis K.; Ehrlich A.; Regenbaum S.; Cohen M.; Ayyash M.; Tikva S.S.; Nahmias Y.; Mechanism and reversal of drug-induced nephrotoxicity on a chip. Sci Transl Med 2021,13(582),eabd6299","journal-title":"Sci Transl Med"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1093\/bib\/bbz165","volume":"22","author":"Su R.","year":"2021","unstructured":"Su R.; Wu H.; Liu X.; Wei L.; Predicting drug-induced hepatotoxicity based on biological feature maps and diverse classification strategies. Brief Bioinform 2021,22(1),428-437","journal-title":"Brief Bioinform"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.3389\/fphar.2020.01321","volume":"11","author":"Yu Z.","year":"2020","unstructured":"Yu Z.; Li L.; Wang C.; He H.; Liu G.; Ma H.; Pang L.; Jiang M.; Lu Q.; Li P.; Qi H.; Cantharidin induces apoptosis and promotes differentiation of AML cells through nuclear receptor Nur77-mediated signaling pathway. Front Pharmacol 2020,11,1321","journal-title":"Front Pharmacol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"104868","DOI":"10.1016\/j.phrs.2020.104868","volume":"158","author":"Zhu M.","year":"2020","unstructured":"Zhu M.; Shi X.; Gong Z.; Su Q.; Yu R.; Wang B.; Yang T.; Dai B.; Zhan Y.; Zhang D.; Zhang Y.; Cantharidin treatment inhibits hepatocellular carcinoma development by regulating the JAK2\/STAT3 and PI3K\/Akt pathways in an EphB4-dependent manner. Pharmacol Res 2020,158,104868","journal-title":"Pharmacol Res"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"108939","DOI":"10.1016\/j.cbi.2020.108939","volume":"317","author":"Song M.","year":"2020","unstructured":"Song M.; Wang X.; Luo Y.; Liu Z.; Tan W.; Ye P.; Fu Z.; Lu F.; Xiang W.; Tang L.; Yao L.; Nie Y.; Xiao J.; Cantharidin suppresses gastric cancer cell migration\/invasion by inhibiting the PI3K\/Akt signaling pathway via CCAT1. Chem Biol Interact 2020,317,108939","journal-title":"Chem Biol Interact"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1208\/s12249-021-02179-4","volume":"23","author":"Wang J.","year":"2022","unstructured":"Wang J.; Gong J.; Wei Z.; Strategies for liposome drug delivery systems to improve tumor treatment efficacy. AAPS PharmSciTech 2022,23(1),27","journal-title":"AAPS PharmSciTech"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1016\/j.xphs.2020.03.001","volume":"109","author":"Zhu K.","year":"2020","unstructured":"Zhu K.; Zhou L.; Zou M.; Ning S.; Liu S.; Zhou Y.; Du K.; Zhang X.; Xia X.; 18-GA-Suc modified liposome loading cantharidin for augmenting hepatic specificity: Preparation, characterization, antitumor effects, and liver-targeting efficiency. J Pharm Sci 2020,109(6),2038-2047","journal-title":"J Pharm Sci"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.3390\/molecules24173080","volume":"24","author":"Zhou L.","year":"2019","unstructured":"Zhou L.; Zou M.; Zhu K.; Ning S.; Xia X.; Development of 11-DGA-3-O-gal-modified cantharidin liposomes for treatment of Hepatocellular carcinoma. Molecules 2019,24(17),3080-3098","journal-title":"Molecules"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.3892\/etm.2018.6416","volume":"16","author":"Zhu J.","year":"2018","unstructured":"Zhu J.; Zhang W.; Wang D.; Li S.; Wu W.; Preparation and characterization of norcantharidin liposomes modified with stearyl glycyrrhetinate. Exp Ther Med 2018,16(3),1639-1646","journal-title":"Exp Ther Med"},{"key":"ref=58","unstructured":"Liu, Y. Phase 1 clinical study for evaluation of pharmacokinetic, safety, tolerance of Norcantharidin lipid microsphere for injection in patients with solid tumor, NCT04673396, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04673396."},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1166\/jbn.2018.2467","volume":"14","author":"Zhang H.","year":"2018","unstructured":"Zhang H.; Jiang Y.; Ni X.; Chen L.; Wu M.; Liu J.; Yang B.; Shan X.; Yang L.; Fan J.; Chen Y.; Wu J.; Fu S.; Glycyrrhetinic acid-modified norcantharidin nanoparticles for active targeted therapy of Hepatocellular carcinoma. J Biomed Nanotechnol 2018,14(1),114-126","journal-title":"J Biomed Nanotechnol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/bcpt.13585","volume":"129","author":"Huang X.","year":"2021","unstructured":"Huang X.; Tang W.; Lin C.; Sa Z.; Xu M.; Liu J.; Wang L.; Li W.; Chen Y.; Yang C.; Protective mechanism of Astragalus polysaccharides against Cantharidin-induced liver injury determined in vivo by liquid chromatography\/mass spectrometry metabolomics. Basic Clin Pharmacol Toxicol 2021,129(1),61-71","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s40360-020-00449-8","volume":"21","author":"Shao H.","year":"2020","unstructured":"Shao H.; Dong L.; Feng Y.; Wang C.; Tong H.; The protective effect of L-glutamine against acute cantharidin-induced cardiotoxicity in the mice. BMC Pharmacol Toxicol 2020,21(1),71-80","journal-title":"BMC Pharmacol Toxicol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"112654","DOI":"10.1016\/j.biopha.2022.112654","volume":"147","author":"Du Y.","year":"2022","unstructured":"Du Y.; Wan H.; Huang P.; Yang J.; He Y.; A critical review of Astragalus polysaccharides: From therapeutic mechanisms to pharmaceutics. Biomed Pharmacother 2022,147,112654","journal-title":"Biomed Pharmacother"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s13205-021-02688-w","volume":"11","author":"Singh R.","year":"2021","unstructured":"Singh R.; Cheng S.; Li J.; Kumar S.; Zeng Q.; Zeng Q.; Norcantharidin combined with 2-deoxy-d-glucose suppresses the hepatocellular carcinoma cells proliferation and migration. 3 Biotech 2021,11(3),142-154","journal-title":"3 Biotech"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41389-018-0102-2","volume":"7","author":"Xu M.D.","year":"2018","unstructured":"Xu M.D.; Liu L.; Wu M.Y.; Jiang M.; Shou L.M.; Wang W.J.; Wu J.; Zhang Y.; Gong F.R.; Chen K.; Tao M.; Zhi Q.; Li W.; The combination of cantharidin and antiangiogenic therapeutics presents additive antitumor effects against pancreatic cancer. Oncogenesis 2018,7(11),94-108","journal-title":"Oncogenesis"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867330666221103151537","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/210626\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867330666221103151537","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T16:22:09Z","timestamp":1693671729000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/210626\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":64,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867330666221103151537","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-04-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-31","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}